Keryx Biopharmaceuticals: My Key Takeaways From Q4 2015 Results

With the current market capitalization of $380.27 million, Keryx (NASDAQ: KERX) might not be your cheapest company to buy in terms of having a stake in their growth story. With growth story like this, there are risks involved. Current earning is still negative although they generated $4.8 million in sales in 4Q 2015, which represented a 46% … Continue reading Keryx Biopharmaceuticals: My Key Takeaways From Q4 2015 Results